P21-Activated Kinase 4 Regulates the Cyclin-Dependent Kinase Inhibitor P57Kip2 in Human Breast Cancer

Anatomical Record

Volumn 296, Issue 10, 2013, Pages 1561-1567

  Li, Yanshu ^a   Wang, Di ^a   Zhang, Hongyan ^a   Wang, Chunyu ^a   Dai, Wei ^a   Cheng, Zhenguo ^a   Wang, Guanqiao ^a   Li, Feng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Degradation; P57Kip2; PAK4; Ubiquitination

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLIN DEPENDENT KINASE INHIBITOR 1C; P21 ACTIVATED KINASE 4; PROTEASOME; UBIQUITIN;

ARTICLE; BREAST CANCER; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR STABILITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM;

CELL CYCLE; DEGRADATION; P57KIP2; PAK4; UBIQUITINATION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P57; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P21-ACTIVATED KINASES; PROTEASOME ENDOPEPTIDASE COMPLEX; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN; UBIQUITINATION;

EID: 84884291469     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.22754     Document Type: Article

References (25)

1. Adams BD, Claffey KP, White BA. 2009. Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells. Endocrinology 150:14-23.
2. Begum A, Imoto I, Kozaki K, Tsuda H, Suzuki E, Amagasa T, Inazawa J. 2009. Identification of PAK4 as a putative target gene for amplification within 19q13.12-q13.2 in oral squamous-cell carcinoma. Cancer Sci 100:1908-1916.
3. Besson A, Dowdy SF, Roberts JM. 2008. CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14:159-169.
4. Borriello A, Caldarelli I, Bencivenga D, Cucciolla V, Oliva A, Usala E, Danise P, Ronzoni L, Perrotta S, Della Ragione F. 2011. p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells. Carcinogenesis 32:10-18.
5. Cammarano MS, Nekrasova T, Noel B, Minden A. 2005. Pak4 induces premature senescence via a pathway requiring p16INK4/p19ARF and mitogen-activated protein kinase signaling. Mol Cell Biol 25:9532-9542.
6. Chen S, Auletta T, Dovirak O, Hutter C, Kuntz K, El-ftesi S, Kendall J, Han H, Von Hoff DD, Ashfaq R, Maitra A, Iacobuzio-Donahue CA, Hruban RH, Lucito R. 2008. Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther 7:1793-1802.
7. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L, Negrini M. 2008. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 27:5651-5661.
8. Fujii S, Tokita K, Wada N, Ito K, Yamauchi C, Ito Y, Ochiai A. 2011. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 30:4118-4128.
9. Guo H, Lv Y, Tian T, Hu TH, Wang WJ, Sui X, Jiang L, Ruan ZP, Nan KJ. 2011. Downregulation of p57 accelerates the growth and invasion of hepatocellular carcinoma. Carcinogenesis 32:1897-1904.
10. Joaquin M, Gubern A, Gonzalez-Nunez D, Josue Ruiz E, Ferreiro I, de Nadal E, Nebreda AR, Posas F. 2012. The p57 CDKi integrates stress signals into cell-cycle progression to promote cell survival upon stress. EMBO J 31:2952-2964.
11. Kavanagh E, Joseph B. 2011. The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta 1816:50-56.
12. Kavanagh E, Vlachos P, Emourgeon V, Rodhe J, Joseph B. 2012. p57(KIP2) control of actin cytoskeleton dynamics is responsible for its mitochondrial pro-apoptotic effect. Cell Death Dis 3:e311.
13. Kim JW, Mori S, Nevins JR. 2010. Myc-induced microRNAs integrate Myc-mediated cell proliferation and cell fate. Cancer Res 70:4820-4828.
14. Kumar R, Gururaj AE, Barnes CJ. 2006. p21-activated kinases in cancer. Nat Rev Cancer 6:459-471.
15. Larson PS, Schlechter BL, King CL, Yang Q, Glass CN, Mack C, Pistey R, de Las Morenas A, Rosenberg CL. 2008. CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer 8:68.
16. Li X, Liu F, Li F. 2010. PAK as a therapeutic target in gastric cancer. Expert Opin Ther Targets 14:419-433.
17. Li Y, Shao Y, Tong Y, Shen T, Zhang J, Gu H, Li F. 2012. Nucleo-cytoplasmic shuttling of PAK4 modulates beta-catenin intracellular translocation and signaling. Biochim Biophys Acta 1823:465-475.
18. Liu Y, Xiao H, Tian Y, Nekrasova T, Hao X, Lee HJ, Suh N, Yang CS, Minden A. 2008. The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice. Mol Cancer Res 6:1215-1224.
19. Lu Z, Hunter T. 2010. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. Cell Cycle 9:2342-2352.
20. Nekrasova T, Minden A. 2011. PAK4 is required for regulation of the cell-cycle regulatory protein p21, and for control of cell-cycle progression. J Cell Biochem 112:1795-1806.
21. Pateras IS, Apostolopoulou K, Niforou K, Kotsinas A, Gorgoulis VG. 2009. p57KIP2: "Kip"ing the cell under control. Mol Cancer Res 7:1902-1919.
22. Qu J, Cammarano MS, Shi Q, Ha KC, de Lanerolle P, Minden A. 2001. Activated PAK4 regulates cell adhesion and anchorage-independent growth. Mol Cell Biol 21:3523-3533.
23. Siu MK, Chan HY, Kong DS, Wong ES, Wong OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, Tsao SW, Stromblad S, Cheung AN. 2010. p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci U S A 107:18622-18627.
24. Worster DT, Schmelzle T, Solimini NL, Lightcap ES, Millard B, Mills GB, Brugge JS, Albeck JG. 2012. Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2. Sci Signal 5:ra19.
25. Yang X, Karuturi RK, Sun F, Aau M, Yu K, Shao R, Miller LD, Tan PB, Yu Q. 2009. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One 4:e5011.